Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Medifast (MED) Share-based Compensation (2016 - 2025)

Medifast's Share-based Compensation history spans 16 years, with the latest figure at $2.2 million for Q4 2025.

For Q4 2025, Share-based Compensation rose 1.88% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $7.6 million, up 3.75%, while the annual FY2025 figure was $7.6 million, 3.75% up from the prior year.
Share-based Compensation reached $2.2 million in Q4 2025 per MED's latest filing, up from $910000.0 in the prior quarter.
In the past five years, Share-based Compensation ranged from a high of $3.3 million in Q4 2021 to a low of $606000.0 in Q1 2023.
Average Share-based Compensation over 5 years is $2.2 million, with a median of $2.3 million recorded in 2021.
The largest YoY upside for Share-based Compensation was 258.25% in 2024 against a maximum downside of 77.35% in 2024.
A 5-year view of Share-based Compensation shows it stood at $3.3 million in 2021, then fell by 10.33% to $2.9 million in 2022, then fell by 18.88% to $2.4 million in 2023, then dropped by 10.91% to $2.1 million in 2024, then rose by 1.88% to $2.2 million in 2025.
Per Business Quant, the three most recent readings for MED's Share-based Compensation are $2.2 million (Q4 2025), $910000.0 (Q3 2025), and $2.6 million (Q2 2025).